ACE-031, Research Reference

ACE-031 is an ActRIIA-IgG1 Fc fusion protein developed by Acceleron Pharma (now part of Merck) that functions as a decoy receptor for myostatin (GDF-8) and related ligands of the TGF-beta (transforming growth factor-beta) superfamily. By presenting the extracellular domain of the activin receptor type IIA (ActRIIA) fused to an immunoglobulin Fc domain, ACE-031 traps and neutralises myostatin and related ligands before they can engage endogenous muscle receptors, thereby removing a principal inhibitory constraint on skeletal muscle growth.

ACE-031 is not a peptide in the conventional sense; it is a fusion protein. It is included here because it is frequently discussed alongside anabolic peptide research in the context of myostatin inhibition and muscular dystrophy research.

Important note: ACE-031 clinical development was discontinued by Acceleron Pharma following observed adverse effects (telangiectasia, epistaxis) in clinical trials. No approved formulation exists. The information on this page is provided as historical and research context only.

Quick Reference

Overview

Myostatin (GDF-8, Growth Differentiation Factor-8) is a member of the TGF-beta superfamily that functions as a potent negative regulator of skeletal muscle mass. Naturally occurring loss-of-function mutations in the myostatin gene in cattle, dogs, and humans produce a hypermuscular phenotype without significant adverse effects in those specific contexts, establishing myostatin inhibition as a validated approach to increasing muscle mass in preclinical and clinical research.

ACE-031 was developed to exploit this biology for therapeutic use in muscle-wasting conditions including Duchenne Muscular Dystrophy (DMD), where the primary pathology (absence of functional dystrophin) causes progressive muscle degeneration. The hypothesis was that blocking myostatin could allow remaining functional muscle tissue to grow and partially compensate for dystrophin-related degeneration.

Research investigated ACE-031 for its potential role in:

• Duchenne Muscular Dystrophy: The primary clinical development focus. Phase 2 trials in boys with DMD reported increases in lean muscle mass, but the programme was halted due to vascular adverse effects before functional endpoint data could be fully established.
• Healthy adult muscle mass: Phase 2 trials in healthy postmenopausal women reported significant lean body mass increases, confirming the anabolic mechanism in non-disease populations. These results established proof-of-concept for the decoy receptor approach.
• General muscle wasting conditions: ACE-031 was positioned as a potential therapeutic for multiple conditions characterised by muscle atrophy, including cancer cachexia and age-related sarcopenia, though trials did not advance in these indications.

Mechanism

ActRIIA Decoy Receptor

ACE-031 is constructed from the extracellular domain of ActRIIA (activin receptor type IIA) fused to the Fc domain of human IgG1. The ActRIIA extracellular domain normally receives signals from myostatin and several related TGF-beta superfamily ligands. As a soluble fusion protein, ACE-031 competes with cell-surface ActRIIA for ligand binding, trapping myostatin and related ligands in the bloodstream before they can engage their endogenous muscle receptors.

The long half-life of approximately 10–12 days arises from the Fc domain, which engages the FcRn (neonatal Fc receptor) recycling pathway, substantially extending the protein’s circulatory half-life compared to unmodified peptides or proteins.

Myostatin Pathway

Once trapped by ACE-031, myostatin cannot engage its functional receptor complex (ActRIIA/ ActRIIB with activin receptor-like kinase partners) on skeletal muscle cells. Myostatin normally activates Smad2/3 signalling downstream, which suppresses muscle growth by inhibiting myogenic differentiation and protein synthesis. By neutralising myostatin, ACE-031 removes this Smad2/3-mediated brake on muscle growth, allowing satellite cell activity and myofibrillar protein synthesis to proceed less constrained.

Ligand Promiscuity and Adverse Effect Mechanism

A critical feature of ACE-031’s pharmacology is its binding to multiple TGF-beta superfamily ligands beyond myostatin, including activin A, GDF-11, activin B, and BMP-9. This broad ligand-binding profile underlies both its potency as an anabolic agent and the adverse effects observed in trials.

BMP-9 (bone morphogenetic protein 9) plays an important role in endothelial cell homeostasis and vascular integrity. Suppression of BMP-9 signalling by ACE-031 is proposed as the mechanism underlying the telangiectasia and epistaxis observed in trial participants. This ligand-promiscuity problem has driven development of more selective myostatin inhibitors in subsequent research, including antibody-based approaches targeting myostatin specifically.

Clinical Trial Data

The following information is drawn from published clinical trial reports. These doses were used in controlled trial settings with medical supervision; they do not constitute an established research community protocol.

Trial Doses

ACE-031 was evaluated subcutaneously at doses ranging from 0.1 mg/kg to 3 mg/kg in Phase 1 and Phase 2 trials. Doses were administered as single or repeated subcutaneous injections at intervals consistent with the compound’s ~10–12 day half-life.

• Phase 1 (healthy volunteers): Single ascending doses from 0.1 to 3 mg/kg; lean body mass increases were dose-dependent and statistically significant
• Phase 2 (postmenopausal women): Multiple doses; significant lean mass increases confirmed; vascular adverse effects began to emerge
• Phase 2 (Duchenne Muscular Dystrophy): Trials in boys with DMD were halted following the safety signal from the adult women trial

Key Trial Findings

Phase 1 and Phase 2 trial data established:

1. Proof-of-concept for lean mass increase: ACE-031 produced statistically and clinically meaningful lean body mass gains at doses above 1 mg/kg, measured by DXA scanning
2. Fat mass reduction: Consistent with effects on body composition, fat mass reductions were also reported alongside lean mass gains
3. Dose-dependent muscle effects: Greater lean mass increases were observed at higher doses (2–3 mg/kg)
4. Adverse effects: Telangiectasia (visible dilated skin blood vessels) and epistaxis (nosebleeds) were observed in a proportion of trial participants, primarily at higher doses. These effects were attributed to BMP-9 suppression and led to programme discontinuation

Reported Side Effects

Reported side effects from clinical trial data include the following.

The vascular adverse effects (telangiectasia, epistaxis, gingival bleeding) were the primary safety finding that led to programme discontinuation. These effects are proposed to result from ACE-031’s suppression of BMP-9 signalling in vascular endothelium, a consequence of the compound’s broad ActRIIA ligand-binding profile. At the doses used in trials, the adverse effect burden was judged to outweigh the anabolic benefit by Acceleron’s clinical team.

No established safe dose without adverse effects was defined before the programme was discontinued. This is an important distinction from compounds that reached dose optimisation. ACE-031 is not a compound with a validated research-community dose range.

ACE-031 in Context: Myostatin Inhibitor Research

ACE-031’s clinical experience illustrates both the validity of the myostatin inhibition concept and the challenge of achieving selectivity in the TGF-beta superfamily:

The myostatin inhibitor field has largely moved toward more selective approaches following the ACE-031 experience, aiming to capture the anabolic benefit while reducing the vascular liability associated with broad TGF-beta superfamily ligand suppression.

Frequently Asked Questions

Why was ACE-031 clinical development discontinued? Clinical development was halted following observed adverse effects in trials: telangiectasia (small dilated blood vessels visible on the skin) and epistaxis (nosebleeds). These vascular effects are attributed to ACE-031’s broad ligand-binding profile. Because ActRIIA binds not only myostatin but also activin A, BMP-9, and other TGF-beta family ligands, suppression of BMP-9 signalling, which is important for endothelial vascular homeostasis, is proposed as the mechanism underlying the vascular side effects. This ligand promiscuity distinguishes ACE-031 from more selective myostatin inhibitors developed subsequently.

How does ACE-031 differ from other myostatin inhibitors? ACE-031 functions as a decoy receptor presenting the full extracellular domain of ActRIIA, trapping myostatin and multiple related TGF-beta ligands. Subsequent approaches have used myostatin-specific antibodies (landogrozumab, trevogrumab) designed for selectivity against myostatin (GDF-8) alone, aiming to reduce vascular adverse effects associated with broader ActRIIA-ligand suppression. Bimagrumab targets the ActRIIA receptor itself. The landscape has evolved substantially toward selectivity since ACE-031’s trials.

What muscle mass results were observed in ACE-031 trials? Published trial data reported meaningful lean muscle mass increases (measured by DXA) following ACE-031 in both healthy volunteers and DMD patients. Phase 2 data in healthy postmenopausal women reported significant lean body mass increases. These results established proof-of-concept for the decoy receptor approach. However, trials were halted before functional or long-term clinical endpoints could be fully established, and the vascular adverse effects were judged to outweigh the muscle mass benefit at trial doses.

Is there an established research community protocol for ACE-031? No. ACE-031 does not have an established research community protocol. Clinical development was discontinued and the compound is not commercially available as a compounded research chemical. The trial doses documented here (0.1–3 mg/kg subcutaneous) are drawn from the clinical literature for informational reference only, not as a guide to research community use. The clinical programme did not advance to a point where a validated safe and effective dosing protocol was established.

Related Pages

Goals: Muscle Growth · Athletic Performance

Also see: IGF-1 (direct anabolic via IGF-1R/mTOR) · Sermorelin (GH secretagogue; GH-mediated anabolism)

References & Further Reading

• Becker C, et al. (2015). Myostatin inhibition, muscle mass and functional outcomes in wasting-associated diseases: long-term effects of ACE-031 treatment of Duchenne muscular dystrophy. Orphanet Journal of Rare Diseases, 10, 78. PubMed
• Padhi D, et al. (2011). A phase I study of a fully human anti-GDF8 monoclonal antibody (MYO-029) in healthy young and elderly adults and patients with Duchenne and Becker muscular dystrophy. Neuromuscular Disorders, 21(4), 259–268. (Reference for context on myostatin antibody approach.)
• Sherman ML, et al. (2013). Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1 [ACE-011]), a novel ligand trap, in adults with Diamond-Blackfan anemia. American Journal of Hematology, 88(7), 591–597. PubMed
• Attie KM, et al. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve, 47(3), 416–423. PubMed